News 24.03.2016

24 March 2016 / 12:12

Ladies and Gentlemen,

On March 24, 2016 in Kardio-Med Silesia, we had a pleasure to hold a meeting concerning plans for research programs that are going to be conducted in our park under the supervision of Professor Józef Dulak, M.D., Ph.D.

“New research tools of personalized medicine: Kardio-Med Silesia as the core facility of modern molecular techniques”

  1. Development of research and methods concerning personalized and precision medicine – creation, registration and development of cell bank for regenerative medicine. Research with use of induced pluripotent stem cells.
  2. Research with use of modern genomics and transcriptomics tools and technologies.
  3. Modern research methods development with use of animal models of human diseases.
  4. Creation of core facility offering modern research tools and technologies facilitating understanding of cardiovascular diseases mechanisms to clinics and research teams from the Silesian Center for Heart Diseases and the Medical University of Silesia.
  5. Organization of science conferences concerning translation research and molecular medicine.
  6. Development of regional scientific cooperation with research centers in southern Poland.
  7. Collaboration with biotechnology industry in terms of research for new medicines and therapy methods.



    This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

    I consent to the processing of my personal data by Śląski Park Technologii Medycznych Kardio-Med Silesia Sp. z o.o., 10C M. Curie-Skłodowskiej St., 41-800 Zabrze, KRS:0000396540, NIP:6482761515, Regon:242742607, as Data Controler in order to receive a response. I can withdraw my consent by submitting a statement to: iod@kmptm.pl. The Data Controler has notified me that this consent does not affect the legality of the processing carried out on the basis of consent before its withdrawal.

    The information clause on the details of the processing is available here.

    Supporting partners:

    Partners: